Patent intelligence · US
US 8383093
Subcutaneous delivery of poly(oxazoline) conjugates
Subcutaneous delivery of poly(oxazoline) conjugates
Patent details — US 8383093
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 26, 2013
- Expiration
- Feb 21, 2033
- Applicant
- Serina Therapeutics, Inc.
- Claims
- 17
- CPC classes
- A61K, A61K31/381, A61K31/4045, A61K31/4462
Quick answer
US 8383093 (Subcutaneous delivery of poly(oxazoline) conjugates) is held by Serina Therapeutics, Inc.. Status: granted. Granted Feb 26, 2013. Expires Feb 21, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Serina Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/381, A61K31/4045, A61K31/4462, A61K31/4535, A61K31/4745
More from Serina Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12383626
Polyoxazoline-drug conjugates with novel pharmacokinetic properties
granted -
US 12383625
Polyoxazoline-drug conjugates with novel pharmacokinetic properties
granted -
US 12233132
Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same
granted -
US 11944618
Subcutaneous delivery of polymer conjugates of therapeutic agents
granted -
US 11925689
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
granted -
US 11766432
Cleavable conjugates of catechol compounds and water-soluble polymers and methods of treatment using the same
granted -
US 11298350
Subcutaneous delivery of polymer conjugates of therapeutics agents
granted -
US 11224595
Subcutaneous delivery of poly(oxazoline) polymer conjugates
granted
Frequently asked questions
What is US patent 8383093?
US 8383093 (Subcutaneous delivery of poly(oxazoline) conjugates) is held by Serina Therapeutics, Inc.. Status: granted. Granted Feb 26, 2013. Expires Feb 21, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8383093?
Serina Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 8383093 expire?
Our index shows an expiration date of Feb 21, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.